Recurrent Treatment in Ovarian Cancer Patients: What Are the Best Regimens and the Order They Should Be Given?

Joanna Glajzer; Jacek P Grabowski; Jalid Sehouli; Jacobus Pfisterer

doi:10.1007/s11864-020-00747-7

Recurrent Treatment in Ovarian Cancer Patients: What Are the Best Regimens and the Order They Should Be Given?

Curr Treat Options Oncol. 2020 Apr 30;21(6):49. doi: 10.1007/s11864-020-00747-7.

Authors

Joanna Glajzer¹, Jacek P Grabowski², Jalid Sehouli², Jacobus Pfisterer³

Affiliations

¹ Department of Gynecology and Center of Oncological Surgery, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin and Berlin Institute of Health, Berlin, Germany. joanna.glajzer@charite.de.
² Department of Gynecology and Center of Oncological Surgery, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin and Berlin Institute of Health, Berlin, Germany.
³ Gynecologic Oncology Center, Kiel, Germany.

PMID: 32350695
DOI: 10.1007/s11864-020-00747-7

Abstract

The choice of the right treatment regimen for recurrent ovarian cancer (rOC) remains a case-by-case decision. It is based on multiple factors that involve patient characteristics and biological factors at the same time. The prioritization of factors is still subject to changes with a trend towards a more personalized medicine. Therefore, participation and engagement in clinical studies constitutes a substantial need for the future development of the treatment algorithm of rOC.

Keywords: Chemotherapy ovarian cancer; PARP inhibitors; Recurrent ovarian cancer; Surgery ovarian cancer recurrence; Treatment ovarian cancer.

Publication types

Review

MeSH terms

Algorithms
Clinical Decision-Making
Combined Modality Therapy / methods
Disease Management
Female
Humans
Ovarian Neoplasms / pathology
Ovarian Neoplasms / therapy*
Recurrence
Retreatment
Treatment Outcome